- Home
- ROOT vs XENE Comparison
ROOT vs XENE Comparison
Compare ROOT & XENE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ROOT
- XENE
- Stock Information
- Founded
- ROOT 2015
- XENE 1996
- Country
- ROOT United States
- XENE Canada
- Employees
- ROOT N/A
- XENE N/A
- Industry
- ROOT Property-Casualty Insurers
- XENE Biotechnology: Pharmaceutical Preparations
- Sector
- ROOT Finance
- XENE Health Care
- Exchange
- ROOT Nasdaq
- XENE Nasdaq
- Market Cap
- ROOT 2.3B
- XENE 2.4B
- IPO Year
- ROOT 2020
- XENE 2014
- Fundamental
- Price
- ROOT $124.70
- XENE $33.18
- Analyst Decision
- ROOT Buy
- XENE Strong Buy
- Analyst Count
- ROOT 6
- XENE 11
- Target Price
- ROOT $134.80
- XENE $54.82
- AVG Volume (30 Days)
- ROOT 448.2K
- XENE 1.5M
- Earning Date
- ROOT 08-06-2025
- XENE 08-07-2025
- Dividend Yield
- ROOT N/A
- XENE N/A
- EPS Growth
- ROOT N/A
- XENE N/A
- EPS
- ROOT 3.16
- XENE N/A
- Revenue
- ROOT $1,271,000,000.00
- XENE $7,500,000.00
- Revenue This Year
- ROOT $22.06
- XENE N/A
- Revenue Next Year
- ROOT $10.86
- XENE $253.71
- P/E Ratio
- ROOT $39.46
- XENE N/A
- Revenue Growth
- ROOT 98.66
- XENE N/A
- 52 Week Low
- ROOT $34.04
- XENE $26.74
- 52 Week High
- ROOT $181.14
- XENE $46.00
- Technical
- Relative Strength Index (RSI)
- ROOT 40.50
- XENE 57.79
- Support Level
- ROOT $122.24
- XENE $31.09
- Resistance Level
- ROOT $130.33
- XENE $32.99
- Average True Range (ATR)
- ROOT 7.74
- XENE 1.21
- MACD
- ROOT -1.68
- XENE 0.20
- Stochastic Oscillator
- ROOT 9.87
- XENE 79.20
About ROOT Root Inc.
Root Inc develops and launches a direct-to-consumer personal automobile insurance and mobile technology company. It generates revenue from the sales of auto insurance policies within the United States.
About XENE Xenon Pharmaceuticals Inc.
Xenon Pharmaceuticals Inc is a neuroscience-focused biopharmaceutical company committed to improving the lives of people living with neurological and psychiatric disorders. It is advancing a novel product pipeline to address areas of high unmet medical need, including epilepsy and depression. The product candidates of the group include XEN1101, NBI-921352, and XEN496 for Epilepsy and Nav1.7 oral inhibitors for Pain.